PT  - JOURNAL ARTICLE
AU  - MEHRAN AFSHAR
AU  - FAWAZ AL-ALLOOSH
AU  - SARAH PIRRIE
AU  - CLARE ROWAN
AU  - NICHOLAS D. JAMES
AU  - EMILIO PORFIRI
TI  - Predictive Factors for Response to Abiraterone in Metastatic Castration Refractory Prostate Cancer
DP  - 2015 Feb 01
TA  - Anticancer Research
PG  - 1057--1063
VI  - 35
IP  - 2
4099  - http://ar.iiarjournals.org/content/35/2/1057.short
4100  - http://ar.iiarjournals.org/content/35/2/1057.full
SO  - Anticancer Res2015 Feb 01; 35
AB  - Background: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolving. Rationalisation of treatment requires identification of those patients more likely to benefit from a particular therapy. We reviewed the outcome of patients treated with abiraterone at our Institution to describe factors predictive for response. Patients and Methods: Patients with CRCP treated with abiraterone were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included overall survival (OS), prostate-specific antigen (PSA) response and time to PSA progression (TTPP). The Kaplan–Meier method and Cox proportional hazards model were used to analyze survival data. Results: A total of 61 patients met the inclusion criteria. In multivariate analysis, three independent predictors of OS were identified: Duration of response to androgen deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p≤0.001). Conclusion: This study has identified three factors predictive for response to abiraterone in CRPC. Duration of response to ADT has not been previously shown to be a predictive factor for patients with CRCP. We suggest that a prospective validation is required.